Search Results 1661-1670 of 23473 for Lesion
measurable by the Olsen Criteria (Olsen, 2011) including at least 1 cutaneous lymphoma lesion ≥2 cm in diameter, assessed locally for eligibility. Patients ...
... lesion (within 2 Barzell zones). An visible lesion on mpMRI, that is accessible to IRE treatment. Must sign a written informed consent. Understands and ...
Weyand says. That study showed the immune cells lacking the CD155 ligands also can be detected in blood and GCA lesions and therefore are new biomarkers of the ...
... lesions. The treated lesion length should be less than the nominal stent length with a reference vessel diameter of 2.50 mm - 4.00 mm. Response of ...
At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 Target Lesion (TL) at baseline. No prior exposure to immune-mediated therapy ...
lesions that may lead to mouth cancer at an early stage, which is when cancer or lesions are easiest to remove and most likely to be cured. Medical ...
... lesions. The treated lesion length should be less than the nominal stent length with a reference vessel diameter of 2.50 mm - 4.00 mm. Phase III Study to ...
All lesions should be treatable by EBRT while meeting normal tissue constraints;. Tumor lesions should be accessible using an US guided approach for ...
... lesion meeting the criteria of RECIST version 1.1; Women of childbearing ... lesions treated by CyberKnife or excisional surgery, clinically stable for ...
Assessment of MRI-detected lesions on screening tomosynthesis in patients with newly diagnosed breast cancer. Clin Imaging. 2020 Jan; 59 (1):50-55 Epub 2019 ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!